SETD2 and neoplasm: Xenograft assays showed that SETD2 overexpression dramatically reduced tumor growth compared with the control group (Figure 8A), while CXCL1 overexpression reversed tumor volume (Figure 8B) and weight (Figure 8C) regardless of the SETD2 expression level.